Tamtam Try Tamtam free
IBA logo

IBA account plan

Particle accelerator technology leader

At a glance

IBA is a Belgian particle-accelerator group in proton therapy, dosimetry, radiopharma and industrial sterilization, with EUR 620.2 million sales in 2025.

IBA (Ion Beam Applications, Louvain-la-Neuve, Belgium) designs and builds particle accelerators for cancer treatment and diagnosis and for industrial uses such as medical device sterilization. It has four activities, Proton Therapy, Dosimetry, RadioPharma Solutions and Industrial Solutions, has sold 700+ accelerators and 80+ proton therapy centers, and has been a Certified B Corporation since 2021. In FY2025 net sales reached a record EUR 620.2 million (+24%), adjusted EBIT EUR 27.4 million and net result EUR 12.7 million, with 2,290 employees. The USA is its largest market, and the employee vehicle Sustainable Anchorage holds 20% of the capital and 30% of the voting rights.

Business units

Strategic priorities

Margin targets to 2028
Revenue CAGR of 5-7% over 2024-2028, OpEx up to 30% of sales and adjusted EBIT around 10% of revenue by 2028; 2026 adjusted EBIT of at least EUR 32 million.
Recurring revenue
Move from a cyclical project-driven model to a multi-business accelerator platform with more service revenue; the EUR 1.6 billion backlog is around half services.
Proton therapy adoption
Grow adoption with clinical evidence and new techniques such as DynamicARC® and ConformalFLASH®, which received FDA IDE approval in June 2026, and expand in the US, Asia and the Gulf.
Nuclear medicine value chain
Combine cyclotron leadership, the ORA radiochemistry platform and alpha-therapy partnerships: PanTera for Ac-225 and Framatome and ACCELERATE.EU for At-211.
Sterilization conversion
Capture the regulatory shift from ethylene oxide and gamma to E-beam and X-ray, with the E-beam/X-ray share expected to rise to over 20% by 2035.

Latest results

In H1 2026 net sales rose 6% to EUR 323.7 million, with IBA Clinical at EUR 196.8 million (+4%) and IBA Technologies at EUR 127.0 million (+10%). Gross margin improved to 33.7% from 29.5%, adjusted EBIT reached EUR 17.6 million against EUR 10.6 million, and the net result was EUR 9.3 million after a loss of EUR 2.6 million a year earlier. Equipment order intake rose 64% to EUR 176 million, driven by proton therapy, while Industrial Solutions orders stayed weak. Net debt rose to EUR 81 million because of working capital and invoicing delays after the SAP S/4HANA go-live. IBA reiterated 2026 adjusted EBIT of at least EUR 32 million.

Investments and deals

ORA Group acquisition
Acquired 80% of ORA and 100% of OOC on 18 December 2025, adding automated PET synthesizers; it was financed by a EUR 50 million acquisition term loan.
PhantomX acquisition
Acquired Berlin-based PhantomX GmbH on 31 October 2025 for AI quality assurance in Dosimetry.
PanTera Ac-225 capacity
PanTera broke ground on a commercial-scale Actinium Production Center (operations expected 2028), and expansion with TerraPower Isotopes and IRE will triple capacity.
SAP S/4HANA ERP
The ERP went live in H1 2026, costing EUR 2.1 million in implementation and temporarily delaying invoicing.
Astatine-211 cyclotron
Launch of Cyclone® iKure for industrial-scale At-211 production, with Framatome applying for the first At-211 site in Nantes.

Challenges and risks

Sterilization overcapacity
Post-COVID investments created overcapacity in sterilization, cutting Industrial order intake; management expects a balanced market around 2028 to 2029.
Working capital and net debt
Back-ended Spanish proton therapy contracts and ERP invoicing delays lifted net debt to EUR 81 million at 30 June 2026, with marked improvement expected only in H2 2027.
Dosimetry under pressure
US and China tariffs, an adverse USD and pressure in conventional radiation therapy pushed Dosimetry to an adjusted EBIT loss in H1 2026.
Lumpy orders and project delays
A small number of large multi-year proton therapy orders drive sales, and delivery delays slow revenue and cash; competition comes from some of the world's largest corporations.
Geopolitics and regulation
US/China tariffs, the loss of control of the Russian subsidiary, country-by-country regulatory approvals and cybersecurity rules (NIS2, MDR, Cyber Resilience Act) are named risks.

What leadership says

“confirmed that IBA is on track with its improved profitability trajectory”

Olivier Legrain, CEO (now Vice-Chairman) · Half Year 2026 results call, 27 August 2026

“Our view remains that this reflects a temporary imbalance between capacity and demand rather than a structural change in market fundamentals”

Henri de Romrée, Deputy CEO · Half Year 2026 results call, 27 August 2026, on sterilization overcapacity

“for us, it's becoming a bit of a religion, 40%, 30%, 10%”

Henri de Romrée, Deputy CEO · Half Year 2026 results call, 27 August 2026, on gross margin, OpEx and EBIT targets

“The guidance that we give is like in 2025, one to beat and not necessarily to meet.”

Catherine Vandenborre, CFO · Full Year 2025 results call, 27 March 2026

Where a supplier can help

Supply chain and manufacturing cost
The gross margin target of 40% and Engineering & Supply Chain work on design-for-manufacturing and more local sourcing favour component suppliers and manufacturing partners that lower cost.
ERP and finance operations
Invoicing delays after the SAP S/4HANA go-live and working-capital pressure point to ERP support, billing and cash-management offers.
Service productivity
Service growth with system availability close to 97% while support workload rose 37%, and AI-enabled troubleshooting, suit field-service, remote monitoring and AI support tools.
Radiopharma and theranostics ecosystem
The nuclear medicine value chain priority (cyclotrons, ORA radiochemistry, Ac-225 and At-211) opens room for radiopharmacy equipment, consumables, regulatory and clinical partners.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like IBA?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about IBA

What does IBA do?

IBA designs and builds particle accelerators: proton therapy systems for cancer treatment, dosimetry quality-assurance tools, cyclotrons and radiochemistry for nuclear medicine, and electron-beam and X-ray systems for industrial sterilization.

What is IBA's revenue?

Net sales were a record EUR 620.2 million in FY2025, up 24%. H1 2026 net sales were EUR 323.7 million, up 6%.

How many employees does IBA have?

IBA had 2,290 employees of 73 nationalities in 2025.

What is IBA's strategy?

IBA aims to become a multi-business accelerator group with more recurring revenue, targeting 5-7% revenue CAGR over 2024-2028 and adjusted EBIT around 10% of revenue by 2028, while expanding along the nuclear-medicine value chain.

Who leads IBA?

Olivier Legrain, CEO since 2012, became Vice-Chairman in June 2026, when Deputy CEO Henri de Romrée took strategic and operational responsibility for all activities. Catherine Vandenborre is Chief Ventures & Corporate Officer, and the Board is chaired by Pierre Mottet.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)